{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:44:15Z","timestamp":1769273055736,"version":"3.49.0"},"reference-count":62,"publisher":"American Physiological Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiological Genomics"],"published-print":{"date-parts":[[2002,10,29]]},"abstract":"<jats:p> Oxidative injury and the resulting death of neurons is a major pathological factor involved in numerous neurodegenerative diseases. However, the development of drugs that target this mechanism remains limited. The goal of this study was to test a compound library of approved Food and Drug Administration drugs against a hydrogen peroxide-induced oxidant injury model in neuroblastoma cells. We identified 26 neuroprotective compounds, of which megestrol, meclizine, verapamil, methazolamide, sulindac, and retinol were examined in greater detail. Using large-scale oligonucleotide microarray analysis, we identified genes modulated by these drugs that might underlie the cytoprotection. Five key genes were either uniformly upregulated or downregulated by all six drug treatments, namely, tissue inhibitor of matrix metalloproteinase (TIMP1), ret-proto-oncogene, clusterin, galanin, and growth associated protein (GAP43). Exogenous addition of the neuropeptide galanin alone conferred survival to oxidant-stressed cells, comparable to that seen with the drugs. Our approach, which we term \u201cinterventional profiling,\u201d represents a general and powerful strategy for identifying new bioactive agents for any biological process, as well as identifying key downstream genes and pathways that are involved. <\/jats:p>","DOI":"10.1152\/physiolgenomics.00064.2002","type":"journal-article","created":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T20:51:41Z","timestamp":1425415901000},"page":"45-52","source":"Crossref","is-referenced-by-count":33,"title":["Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays"],"prefix":"10.1152","volume":"11","author":[{"given":"Satinder S.","family":"Sarang","sequence":"first","affiliation":[{"name":"Biotechnology Center, Center for Neurologic Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Biotechnology Center, Center for Neurologic Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolphe","family":"Cadet","sequence":"additional","affiliation":[{"name":"Biotechnology Center, Center for Neurologic Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Valeras","sequence":"additional","affiliation":[{"name":"Biotechnology Center, Center for Neurologic Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick V.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Biotechnology Center, Center for Neurologic Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Gullans","sequence":"additional","affiliation":[{"name":"Biotechnology Center, Center for Neurologic Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"24","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19970401)48:1<63::AID-JNR6>3.0.CO;2-C"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2001.5159"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00253-1"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10087"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1998.71031321.x"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Bowling AC, Barkowski EE, McKenna-Yasek D, Sapp P, Horvitz HR, Beal MF, and Brown RH Jr. Superoxide dismutase concentration and activity in familial amyotrophic lateral sclerosis. J Neurochem 64: 2366\u20132369, 1995.","DOI":"10.1046\/j.1471-4159.1995.64052366.x"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(96)00404-2"},{"key":"R8","unstructured":"Butte AJ, Ye J, Haring HU, Stumvoll M, White MF, and Kohane IS. Determining significant fold differences in gene expression analysis. Pac Symp Biocomput : 6\u201317, 2001."},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.2174\/0929867013373048"},{"key":"R10","unstructured":"Chang AY. Megestrol acetate as a biomodulator. Semin Oncol 25: 58\u201361, 1998."},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200109170-00017"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Cookson MR and Shaw PJ. Oxidative stress and motor neurone disease. Brain Pathol 9: 165\u2013186, 1999.","DOI":"10.1111\/j.1750-3639.1999.tb00217.x"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/131.12.3208"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410212"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0279fje"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1038\/4475"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(99)00249-X"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006797522521"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1152\/physiolgenomics.2001.5.4.161"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1007\/s004010050815"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5493.985"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.36.1.103"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390203"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.26.3009"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10091"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.12.1975"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.5.1047"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Hayward LJ, Rodriguez JA, Kim JW, Tiwari A, Goto JJ, Cabelli DE, Valentine JS, and Brown RH Jr. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial ALS. J Biol Chem, 2002.","DOI":"10.1074\/jbc.M112087200"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.210221897"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006988528655"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.2144\/02322st06"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(00)00419-6"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(02)00016-2"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2000.741158.x"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-4165(00)00181-1"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M011000200"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19970615)48:6<571::AID-JNR10>3.0.CO;2-Y"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(96)00198-2"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1296-1675"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6_Suppl_4.228S"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2001.01475.x"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.1.127"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00412-5"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1021\/bi000169p"},{"key":"R45","unstructured":"Mitsumoto H. Clinical trials: present and future. Amyotroph Lateral Scler Other Motor Neuron Disord 2, Suppl 1: S10\u2013S14, 2001."},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.29.20251"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.2.179"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.2466\/pms.1997.85.3f.1163"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.210254597"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.26.15763"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1007\/BF01965406"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1006\/jbin.2001.1005"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1038\/73432"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.1038\/73439"},{"key":"R55","unstructured":"Silani V, Braga M, Cardin V, and Scarlato G. The pathogenesis of ALS: implications for treatment strategies. Neurol Neurochir Pol 35: 25\u201339, 2001."},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-200111000-00005"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1999.00531.x"},{"key":"R58","doi-asserted-by":"publisher","DOI":"10.1038\/35102591"},{"key":"R59","doi-asserted-by":"publisher","DOI":"10.1038\/nm0901-977"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5298.343"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1297-1359"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2000.0319"}],"container-title":["Physiological Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.physiology.org\/doi\/pdf\/10.1152\/physiolgenomics.00064.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T22:16:29Z","timestamp":1567980989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.physiology.org\/doi\/10.1152\/physiolgenomics.00064.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,29]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,10,29]]}},"alternative-id":["10.1152\/physiolgenomics.00064.2002"],"URL":"https:\/\/doi.org\/10.1152\/physiolgenomics.00064.2002","relation":{},"ISSN":["1094-8341","1531-2267"],"issn-type":[{"value":"1094-8341","type":"print"},{"value":"1531-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,29]]}}}